Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies

NCT02030067 is registered in ClinicalTrials.gov with Processa Pharmaceuticals as lead sponsor.

NCT NCT02030067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02030067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies
Lead sponsor
Processa Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2013
Completion date
December 31, 2019
Enrollment
127 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic bladder cancer, solid tumor